Previous 10 | Next 10 |
SAN DIEGO , June 4, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 41 st Annual Global Healthcare Conference Webcast at 9:40 a.m. ET on Thursday , June 11, 2020. Kevin Gorman , Chief Executive Officer, Eiry Roberts, Chief Medical...
Have you ever found yourself saying a stock is too expensive because it's made a big move in a short period of time? Or that a stock is too cheap to ignore because its price has fallen sharply? Anchoring bias, or the tendency to fixate on a past price when considering a new investment idea, ca...
NORTH CHICAGO, Ill. , May 29, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), announced that the U.S. Food and Drug Administration (FDA) approved ORIAHNN™ (elagolix, estradiol, and norethindrone acetate capsu...
SAN DIEGO , May 26, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday , June 2, 2020. Kevin Gorman , Chief Executive Officer, will present at the conference. The liv...
SAN DIEGO , May 14, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the RBC Capital Markets 2020 Global Healthcare Conference at 3:40 p.m. ET on Tuesday , May 19, 2020. Kevin Gorman , Chief Executive Officer, will present at the conference. ...
Neurocrine Biosciences (NASDAQ: NBIX) had a big day Tuesday, the latest in a string of good days. Since the stock bottomed out at $75.11 almost two months ago, it climbed as high as $119.65 on Tuesday, a jump of 44.5%, though it closed at $112.60. This is a run that may continue, despite any...
SAN DIEGO , May 13, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that multiple scientific presentations and abstracts from its movement disorder programs will be available on the 2020 American Academy of Neurology (AAN) Annual Meeting Science Highlights...
Neurocrine Biosciences (NASDAQ: NBIX ) has exercised its option to in-license global rights Idorsia's ( OTCPK:IDRSF ) ACT-709478, an orally available brain-penetrating T-type calcium blocker for the potential treatment of a rare type of pediatric epilepsy. More news on: Neurocrine B...
SAN DIEGO and ALLSCHWIL, Switzerland , May 11, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Idorsia Ltd (SIX: IDIA) today announced, following Investigational New Drug (IND) application acceptance by the U.S. Food and Drug Administration (FDA), Neurocr...
Investors rewarded Neurocrine Biosciences (NASDAQ: NBIX) on Wednesday for posting a Q1 of fiscal 2020 earnings report that featured encouraging growth in key financials. The biotech company published the quarterly release after market hours on Tuesday, revealing that it booked...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...